“Our own analysis shows that, in general, 50% of patients are not receiving an optimal chemotherapy dosage which reduces the effectiveness of the treatment or causes significant toxicity,” said Kevin Harter, Chairman, President and CEO of Saladax Biomedical. “MyImatinib enables oncologists to administer tailored, personalized doses to chronic myeloid leukemia and gastrointestinal stromal tumor patients, allowing for optimal drug exposure and adherence over the course of their treatment.” Read more: http://bit.ly/1w8dABc
Client & Alumni News
Saladax Biomedical Announces U.S. Launch of MyImatinib Chemotherapy Exposure Optimization Test
The Ben Franklin Technology Partners is an initiative of the Pennsylvania Department of Community and Economic Development and is funded by the Ben Franklin Technology Development Authority.